NCT00083031View on ClinicalTrials.gov

Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2009

Conditions
Breast Cancer
Interventions
DRUG

bevacizumab

DRUG

cyclophosphamide

DRUG

methotrexate

Trial Locations (4)

37203

Sarah Cannon Research Institute, Nashville

02114

Massachusetts General Hosptial, Boston

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Genentech, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER